Methods of treating tumors

A method of treating renal cell carcinoma in a human subject in need thereof, comprising subcutaneously administering to the subject in a period between 3 minutes and 5 minutes a pharmaceutical composition comprising (i) nivolumab at 120 mg/ml and (ii) a hyaluronidase comprising the amino acid sequence as set forth in SEQ ID NO:

• 5;
• wherein 1200 mg of nivolumab and 20,000 units of the hyaluronidase are administered in a single unit flat dose once every four weeks.

A method of treating renal cell carcinoma in a human subject in need thereof, comprising subcutaneously administering to the subject in a period between 3 minutes and 5 minutes a pharmaceutical composition comprising (i) nivolumab and (ii) a hyaluronidase comprising the amino acid sequence as set forth in SEQ ID NO:

• 5;
• wherein 600 mg of nivolumab and 10,000 units of the hyaluronidase are administered in a total administered volume of 5 mL in a single unit flat dose once every two weeks.

A method of treating renal cell carcinoma in a human subject in need thereof, comprising subcutaneously administering to the subject a pharmaceutical composition comprising (i) nivolumab and (ii) a hyaluronidase comprising the amino acid sequence as set forth in SEQ ID NO:

• 5;
• wherein 900 mg of nivolumab and 15,000 units of the hyaluronidase are administered in a single unit flat dose every three weeks.

A method of treating renal cell carcinoma in a human subject in need thereof, comprising subcutaneously administering to the subject a pharmaceutical composition comprising (i) nivolumab and (ii) a hyaluronidase;

• (1) wherein 1200 mg of nivolumab and 20,000 units of the hyaluronidase are administered in a single unit flat dose once every four weeks;
• (2) wherein 900 mg of nivolumab and 15,000 units of the hyaluronidase are administered in a single unit flat dose once every three weeks;
• or (3) wherein 600 mg of nivolumab and 10,000 units of the hyaluronidase are administered in a single unit flat dose once every two weeks.